EUVIMEDEUVIMED entdecken
Crossref

Distinct Gut Microbiome Signatures of Complete Responders to Omalizumab in Chronic Spontaneous Urticaria

Yung-Tsu Cho iD, Chia-Yu Chu

Experimental Dermatology · 2026

DOI: 10.1111/exd.70208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2026. Verfasst von Yung-Tsu Cho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: The Ministry of Science and Technology of Taiwan, National Taiwan University Hospital, Novartis Taiwan Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota composition of patients with chronic spontaneous urticaria (CSU) has been shown to be different from that of healthy controls. However, whether the gut microbiome is different between CSU patients with different treatment responses to omalizumab is seldom examined and is largely unknown. Antihistamine‐refractory CSU patients were enrolled to receive three injections of omalizumab. The patients were divided into two groups based on their treatment responses to omalizumab determined using the weekly urticarial activity score. Demographic data, blood samples and faecal specimens were collected before, during and after omalizumab treatment. Faecal specimens underwent bacterial 16S ribosomal RNA sequencing to determine the gut bacterial microbiome. Serum biomarkers were examined using enzyme‐linked immunosorbent assay. Fourteen patients were enrolled and were divided into two groups: complete responders (CRs) and non‐complete responders (NCRs). At baseline, the α‐diversity indices of the CR group were higher than those of the NCR group. The bacterial microbiota composition was different between the groups, but these differences became less obvious after omalizumab treatment. At baseline, the genera Bacteroides , Lactobacillus , Prevotella_9 , Butyricimonas , Dialister , Megasphaera and Ruminococcaceae_UCG‐002 were more abundant in the CR group. In addition, the changes in the IL‐33 and IL‐17 levels after omalizumab treatment were correlated with the changes in the relative abundances of Dialister ( r = 0.929, p = 0.003) and Ruminococcaceae‐UCG‐002 ( r = −0.828, p = 0.022), respectively. In conclusion, the CR patients' distinct and characteristic gut bacterial microbiota profile before treatment may contribute to their better responses to omalizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsGastrointestinal MicrobiomeHumansFemaleMaleAdultMiddle AgedTreatment OutcomeBiomarkersFecesRNA, Ribosomal, 16SYoung Adult

Stichwörter der Autor:innen

biomarkerchronic spontaneous urticariamicrobiomeomalizumab

Substanzen

OmalizumabAnti-Allergic AgentsBiomarkersRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

ORCID-Profile: Yung-Tsu Cho

Förderung

  • The Ministry of Science and Technology of Taiwan
  • National Taiwan University Hospital
  • Novartis Taiwan Co. Ltd

Zitieren

APA

Cho, Y. T., & Chu, C. Y. (2026). Distinct Gut Microbiome Signatures of Complete Responders to Omalizumab in Chronic Spontaneous Urticaria. Experimental Dermatology. https://doi.org/10.1111/exd.70208

Vancouver

Cho YT, Chu CY. Distinct Gut Microbiome Signatures of Complete Responders to Omalizumab in Chronic Spontaneous Urticaria. Experimental Dermatology. 2026. doi:10.1111/exd.70208

BibTeX
@article{Cho2026,
  author = {Cho, Yung-Tsu and Chu, Chia-Yu},
  title = {Distinct Gut Microbiome Signatures of Complete Responders to Omalizumab in Chronic Spontaneous Urticaria},
  journal = {Experimental Dermatology},
  year = {2026},
  doi = {10.1111/exd.70208}
}
Kostenlos starten →